1. Academic Validation
  2. Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma

Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma

  • Sci Rep. 2017 Sep 8;7(1):11026. doi: 10.1038/s41598-017-11389-5.
Tomonori Higuchi 1 Yumiko Hashida 1 Ayuko Taniguchi 2 Mikio Kamioka 3 Masanori Daibata 4
Affiliations

Affiliations

  • 1 Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi, 783-8505, Japan.
  • 2 Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi, 783-8505, Japan.
  • 3 Department of Laboratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi, 783-8505, Japan.
  • 4 Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi, 783-8505, Japan. [email protected].
Abstract

The genetic events that lead to aggressive transformation of cases of splenic marginal zone lymphoma (SMZL) after the chronic clinical stage have not been well understood. We aimed to find candidate genes associated with aggressive features of SMZL. We have successfully established two SMZL cell lines, designated SL-15 and SL-22, derived from the same patient's tumor clone in chronic and aggressive phases, respectively. Microarray analysis identified cell cycle-associated genes-specifically PLK1-as the most significantly upregulated in primary aggressive SMZL cells compared with cells from chronic phase. EphA4 and MS4A1 (CD20) were found to be downregulated dramatically. These gene expression patterns were reproduced in both cell lines. Genetic knockdown of PLK1 resulted in inhibition of cell proliferation and induction of Apoptosis in SL-22 cells, which expressed higher levels of PLK1 than SL-15 cells. SL-22 cells needed higher concentrations of chemical PLK1 inhibitors to achieve greater effects. In addition, we found homozygous deletion of the MS4A1 gene as a newly identified molecular mechanism of CD20-negative conversion. Our findings are expected to stimulate further studies on whether PLK1 could be a potential therapeutic target for this tumor. Furthermore, cases with CD20-negatively converted lymphomas should be screened for the genomic loss of MS4A1.

Figures
Products